Bosentan: new indication. Also too risky in mildly symptomatic pulmonary arterial hypertension. No proven tangible benefit in mildly symptomatic patients, and too many adverse effects.

  • Published 2009 in Prescrire international
Sorry, there's nothing here.

Topics

Cite this paper

@article{2009BosentanNI, title={Bosentan: new indication. Also too risky in mildly symptomatic pulmonary arterial hypertension. No proven tangible benefit in mildly symptomatic patients, and too many adverse effects.}, author={}, journal={Prescrire international}, year={2009}, volume={18 100}, pages={55} }